TY  - JOUR
AU  - Shi, Wenfang 
AU  - Yu, Mingxia 
AU  - Qian, Qijun 
PY  - 2008
TI  - AAV-Based Targeting Gene Therapy
JF  - American Journal of Immunology
VL  - 4
IS  - 4
DO  - 10.3844/ajisp.2008.51.65
UR  - https://thescipub.com/abstract/ajisp.2008.51.65
AB  - Since the first parvovirus serotype AAV2 was isolated from human and used as a vector for gene therapy application, there have been significant progresses in AAV vector development. AAV vectors have been extensively investigated in gene therapy for a broad application. AAV vectors have been considered as the first choice of vector due to efficient infectivity, stable expression and nonpathogenicity. However, the untoward events in AAV mediated in vivo gene therapy studies proposed the new challenges for their further applications. Deep understanding of the viral life cycle, viral structure and replication, infection mechanism and efficiency of AAV DNA integration, in terms of contributing viral, host-cell factors and circumstances would promote to evaluate the advantages and disadvantages and provide more insightful information for the possible clinical applications. In this review, main effort will be focused on the recent progresses in gene delivery to the target cells via receptor-ligand interaction and DNA specific integration regulation. Furthermore AAV receptor and virus particle intracellular trafficking are also discussed.